<DOC>
	<DOCNO>NCT00981162</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose everolimus give together sorafenib tosylate see well work treat patient advance solid tumor metastatic pancreatic cancer respond gemcitabine hydrochloride . Sorafenib tosylate everolimus may stop growth tumor cell block enzymes need cell growth . Sorafenib tosylate may also stop growth pancreatic cancer block blood flow tumor . Giving sorafenib tosylate together everolimus may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib Tosylate Everolimus Treating Patients With Advanced Solid Tumors Metastatic Pancreatic Cancer That Does Not Respond Gemcitabine Hydrochloride</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 6-month overall survival patient previously treat gemcitabine ( gemcitabine hydrochloride ) -refractory metastatic pancreatic cancer treat combination sorafenib ( sorafenib tosylate ) everolimus . II . To determine recommended Phase II dose everolimus administer combination sorafenib patient advance solid tumor . SECONDARY OBJECTIVES : I . To determine response rate , median survival , time progression , CA 19.9 decline toxicity spectrum combination patient population . II . To characterize pharmacokinetic ( PK ) profile sorafenib everolimus give combination . III . To explore biomarkers correlate response study combination patient previously treat gemcitabine-refractory metastatic pancreas cancer . OUTLINE : This phase I , dose-escalation study everolimus , follow phase II study . Patients receive everolimus ( PO ) daily sorafenib tosylate PO twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Acinar Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Phase I : Histologically cytologically confirm solid tumor advance refractory lack lifeprolonging treatment ; patient histologically cytologically confirm renal cell carcinoma hepatocellular carcinoma eligible Phase II : Histologically cytologically proven metastatic adenocarcinoma pancreas progress one prior gemcitabine contain regimen , progress within 6 month completion gemcitabine contain adjuvant regimen Patients must measurable assessable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate hematological , renal liver function determine follow : Absolute neutrophil count ( ANC ) &gt; 1500 cells/mm^3 Hemoglobin &gt; = 9g/dL Platelets &gt; = 100,000 cells/mm^3 Serum creatinine within institutional upper limit normal ( ULN ) OR &gt; = 60mll/min patient creatinine level institutional ULN Bilirubin = &lt; 1.5 x ULN Alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) = &lt; 2.5 time ULN ( &lt; 5 x ULN patient abnormal value attributable liver metastasis ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 time ULN ( &lt; 5 x ULN patient abnormal value attributable liver metastasis ) International normalize ratio ( INR ) = &lt; 1.5 ( Anticoagulation allow target INR = &lt; 1.5 stable dose warfarin stable dose lowmolecularweight ( LMW ) heparin &gt; 2 week first dose study agent ) Fasting serum cholesterol = &lt; 300 mg/dL OR = &lt; 7.75 mmol/L AND Fasting triglyceride = &lt; 2.5 x ULN ; NOTE : case one threshold exceed , patient include initiation appropriate lipid lower medication Ability understand willingness sign write informed consent ; sign informed consent must obtain prior study specific procedure Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation ; men use adequate birth control least three month last administration sorafenib everolimus Phase II : Patients histological cryological diagnosis consistent adenocarcinoma include adenosquamous , islet cell , cystoadenoma cystadenocarcinoma , carcinoid , small large cell carcinoma lymphoma Phase II : Adenocarcinoma arise site pancreas ( distal bile duct , ampulla vater periampullary duodenum ) Prior therapy approve investigational agent within 4 week prior start treatment plan protocol Uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN Any active infection Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) ; patient must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management Cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; = Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; = CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture Known suspect allergy sorafenib , everolimus , rapamycins ( sirolimus , temsirolimus ) , excipients , agent give course trial Any condition impair patient 's ability swallow whole pill Any malabsorption problem Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day first study drug Urine protein : creatinine ratio &gt; =1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month baseline Inability comply study and/or followup procedure History concurrent malignancy history second malignancy within past 5 year Unable provide inform consent Concomitant use medication substance inhibitor inducer CYP3A enzyme , include limited phenytoin , carbamazepine , barbiturate , rifampin , Phenobarbital St. Johns Wort Phase II : Prior treatment mTOR inhibitor ( e.g. , sirolimus , temsirolimus , everolimus ) RasMAPK inhibitor ( e.g. , sorafenib ) Any unresolved chronic toxicity great CTCAE grade 2 previous anticancer therapy ( except alopecia ) Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent ; topical inhale corticosteroid allow Patients receive immunization attenuate live vaccine within one week study entry study period ; close contact receive attenuated live vaccine avoid treatment everolimus ( Examples live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine ) Severely impaired lung function define spirometry diffuse capacity carbon monoxide ( DLCO ) 50 % normal predict value and/or O2 saturation 88 % less rest room air ; patient require undergo mandatory respiratory function test screen eligible unless medically necessary Severe and/or uncontrolled nonmalignant liver disease cirrhosis severe hepatic impairment define ChildPugh class C A known history human immunodeficiency virus ( HIV ) seropositivity Female patient pregnant breast feeding , adult reproductive potential use effective birth control method ; barrier contraceptive use , must continue throughout trial sex ; hormonal contraceptive acceptable sole method contraception Women childbearing potential ( WOCBP ) positive urine serum pregnancy test within 7 day prior start treatment Male patient whose sexual partner ( ) WOCBP willing use adequate contraception study 8 week end treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>